These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
655 related articles for article (PubMed ID: 25916665)
1. Immunomodulatory therapies for relapsing-remitting multiple sclerosis: monoclonal antibodies, currently approved and in testing. Craddock J; Markovic-Plese S Expert Rev Clin Pharmacol; 2015 May; 8(3):283-96. PubMed ID: 25916665 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of monoclonal antibody therapies for relapsing remitting multiple sclerosis: A network meta-analysis. Xu X; Chi S; Wang Q; Li C; Xu B; Zhang J; Chen X Mult Scler Relat Disord; 2018 Oct; 25():322-328. PubMed ID: 30195200 [TBL] [Abstract][Full Text] [Related]
3. An update on new and emerging therapies for relapsing-remitting multiple sclerosis. Weinstock-Guttman B Am J Manag Care; 2013 Nov; 19(17 Suppl):s343-54. PubMed ID: 24494635 [TBL] [Abstract][Full Text] [Related]
4. Safety of monoclonal antibodies for the treatment of multiple sclerosis. McGinley MP; Moss BP; Cohen JA Expert Opin Drug Saf; 2017 Jan; 16(1):89-100. PubMed ID: 27756172 [TBL] [Abstract][Full Text] [Related]
5. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Wingerchuk DM; Carter JL Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135 [TBL] [Abstract][Full Text] [Related]
9. Advances in the treatment of relapsing-remitting multiple sclerosis. Tanasescu R; Ionete C; Chou IJ; Constantinescu CS Biomed J; 2014; 37(2):41-9. PubMed ID: 24732658 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries. Putzki N; Yaldizli O; Mäurer M; Cursiefen S; Kuckert S; Klawe C; Maschke M; Tettenborn B; Limmroth V Eur J Neurol; 2010 Jan; 17(1):31-7. PubMed ID: 19614963 [TBL] [Abstract][Full Text] [Related]